Objectives To determine prevalence of post-MI LV thrombus in the current era, and develop an effective algorithm – predicated on echocardiography (echo) - to discern patients warranting further testing for thrombus via delayed-enhancement (DE-) CMR. Background LV thrombus impacts post-MI management. DE-CMR provides thrombus tissue characterization and is well validated but an impractical screening modality for all post-MI patients. Methods Same day echo and CMR were performed via a tailored protocol, which entailed uniform echo contrast (irrespective of image quality) and dedicated DE-CMR for thrombus tissue characterization. Results 201 patients were studied; 8% had thrombus via DE-CMR. All thrombi were apically located – 94% occurred with LAD MI. Whereas patients with thrombus had more prolonged chest pain and larger MI (p≤0.01), only 18% had aneurysm on echo (cine-CMR 24%). Non-contrast (35%) and contrast echo (64%) yielded limited sensitivity for thrombus on DE-CMR. Thrombus was associated with stepwise increments in basal → apical contractile dysfunction on echo and quantitative cine-CMR; echo-measured apical wall motion score was higher among patients with thrombus (p<0.001) and paralleled cine-CMR decrements in apical EF and peak ejection rates (both p<0.005). Thrombus-associated decrements in apical contractile dysfunction were significant even among patients with LAD infarction (p<0.05). Echo-based apical wall motion score improved overall performance (AUC 0.89±0.44) for thrombus compared to EF (AUC 0.80±0.61; p=0.01): Apical wall motion partitions would have enabled all patients with LV thrombus to be appropriately referred for DE-CMR (100% sensitivity and negative predictive value), while avoiding further testing in over half (56–63%) of patients. Conclusions LV thrombus remains common especially after LAD MI, and can occur even in absence of aneurysm. Whereas DE-CMR yields improved overall thrombus detection, apical wall motion on non-contrast echo can be used as an effective stratification tool to identify patients in whom DE-CMR thrombus assessment is most warranted.

BackgroundNon-ischemic fibrosis (NIF) on cardiac magnetic resonance (CMR) has been linked to poor prognosis, but its association with adverse right ventricular (RV) remodeling is unknown. This study examined a broad cohort of patients with RV dysfunction, so as to identify relationships between NIF and RV remodeling indices, including RV pressure load, volume and wall stress.Methods and ResultsThe population comprised patients with RV dysfunction (EF<50%) undergoing CMR and transthoracic echo within a 14 day (5±3) interval. Cardiac structure, function, and NIF were assessed on CMR. Pulmonary artery systolic pressure (PASP) was measured on echo. 118 patients with RV dysfunction were studied, among whom 47% had NIF. Patients with NIF had lower RVEF (34±10 vs. 39±9%; p = 0.01) but similar LVEF (40±21 vs. 39±18%; p = 0.7) and LV volumes (p = NS). RV wall stress was higher with NIF (17±7 vs. 12±6 kPa; p<0.001) corresponding to increased RV end-systolic volume (143±79 vs. 110±36 ml; p = 0.006), myocardial mass (60±21 vs. 53±17 gm; p = 0.04), and PASP (52±18 vs. 41±18 mmHg; p = 0.001). NIF was associated with increased wall stress among subgroups with isolated RV (p = 0.005) and both RV and LV dysfunction (p = 0.003). In multivariable analysis, NIF was independently associated with RV volume (OR = 1.17 per 10 ml, [CI 1.04–1.32]; p = 0.01) and PASP (OR = 1.43 per 10 mmHg, [1.14–1.81]; p = 0.002) but not RV mass (OR = 0.91 per 10 gm, [0.69–1.20]; p = 0.5) [model χ2 = 21; p<0.001]. NIF prevalence was higher in relation to PA pressure and RV dilation and was > 6-fold more common in the highest, vs. the lowest, common tertile of PASP and RV size (p<0.001).ConclusionAmong wall stress components, NIF was independently associated with RV chamber dilation and afterload, supporting the concept that NIF is linked to adverse RV chamber remodeling.

Objective Ischemic mitral regurgitation (MR) is common, but its response to percutaneous coronary intervention (PCI) is poorly understood. This study tested utility of myocardial perfusion imaging (MPI) for stratification of MR response to PCI. Methods MPI and echo were performed among patients undergoing PCI. MPI was used to assess stress/rest myocardial perfusion. MR was assessed via echo (performed pre- and post-PCI). Results 317 patients with abnormal myocardial perfusion on MPI underwent echo 25±39 days prior to PCI. MR was present in 52%, among whom 24% had advanced (≥moderate) MR. MR was associated with LV chamber dilation on MPI and echo (both p<0.001). Magnitude of global LV perfusion deficits increased in relation to MR severity (p<0.01). Perfusion differences were greatest for global summed rest scores, which were 1.6-fold higher among patients with advanced MR vs. those with mild MR (p=0.004), and 2.4-fold higher vs. those without MR (p<0.001). In multivariate analysis, advanced MR was associated with fixed perfusion defect size on MPI (OR 1.16 per segment [CI 1.002–1.34], p=0.046) independent of LV volume (OR 1.10 per 10ml [CI 1.04–1.17], p=0.002). Follow-up via echo (1.0±0.6 years) demonstrated MR to decrease (≥1 grade) in 31% of patients, and increase in 12%. Patients with increased MR after PCI had more severe inferior perfusion defects on baseline MPI (p=0.028), whereas defects in other distributions and LV volumes were similar (p=NS). Conclusions Extent and distribution of SPECT-evidenced myocardial perfusion defects impacts MR response to revascularization. Increased magnitude of inferior fixed perfusion defects predicts post-PCI progression of MR.

No abstract

Background: In 2014, UNICANCER, composed of 18 French Comprehensive Cancer Centers, launched the Epidemiological Strategy and Medical Economics (ESME) program to investigate real-world data in oncology. Real-world data give the opportunity to assess the activity of specific products outside the framework of clinical trials. Oral vinorelbine (OV) is one of the therapeutic options available for metastatic breast cancer (mBC). Few data are available regarding its real clinical efficiency in current practice. We aimed at evaluating such activity within the ESME population. Methods: The ESME-mBC database was built from information systems, treatment databases and patients' electronic files, with homogenous on-site collected information and high-level quality-control (Delaloge et al, Ann. Oncol 2016 (in press)). All patients having started a systemic treatment for mBC in a cancer center participating in the ESME program between 01-Jan-2008 and 31-Dec-2013 have been selected into the database. For the purpose of the current analyses, data cut-off was July, 2015 and all patients who received OV at any time during the course of their disease were selected and analyzed. Primary end point was progression-free survival (PFS) from initiation of OV. Secondary end points were descriptive and prognostic analyses, and overall survival (OS). Results: Among 13.853 patients recorded in the ESME-mBC database, 1402 received OV as a monotherapy or in combination (809 and 593 patients / 57.7% and 42.3% respectively). Most frequent combinations were with capecitabine (368 patients) and anti-HER2 therapy (165 patients). De-novo mBC was observed in 282 patients (20.1%) and 569 patients (40.6%) had only non-visceral metastases. At metastatic diagnosis, 221 patients (16.9%) had HER2-positive and 298 patients (22.9%) triple-negative tumors respectively. At OV initiation, median age was 59.0 [IC95%: 50-67] years. Endocrine therapy was given prior OV in 769 patients (54.9%). For PFS analysis, 1345 patients were evaluable. The following table summarizes PFS results according to the treatment patterns and the OV-line. PFS results according to the treatment patterns and the OV-line  OV-line  1st line2nd line3rd line4th line and moreOverall populationN320414313270Overall populationPFS (months, [IC95%])4.7 [4.2-5.5]3.3 [3.0-3.5]2.9 [2.6-3.2]2.3 [2.1-2.4]OV monotherapyN118223207202OV monotherapyPFS (months, [IC95%])4.3 [3.1-5.3]3.2 [2.9-3.5]2.8 [2.5-3.2]2.2 [2.0-2.4]OV in combination with capecitabineN1531294925OV in combination with capecitabinePFS (months, [IC95%])5.1 [3.9-6.1]3.5 [2.8-4.6]3.0 [2.4-4.7]2.0 [1.4-5.2]OV in combination with anti-HER2N41503826OV in combination with anti-HER2PFS (months, [IC95%])6.0 [4.1-7.9]3.1 [2.4-3.8]3.3 [2.4-6.0]2.7 [1.9-3.7] Following diagnosis of mBC, median OS was 38.2 months [IC95%: 36.1-40.0] in the cohort of patients who received OV at any time. Conclusions:This study allows large scale assessment of real life benefit of OV over subsequent lines and shows that OV yields clinical benefit even in heavily pre-treated mBC patients. Citation Format: Pierre H, Mahasti S, Damien P, Nicolas M, Chritelle L, Florence D, Mony U, Lionel U, William J, Paule A, Audrey M, Claudia L, Mario C, Marie-Paule S, Marie-Ange M-R, Marianne L, Jean-Christophe E, Thierry P, Jean-Marc F, Bruno C, Anthony G, Christian C, Gaëtane S, David P. Real-life activity of oral vinorelbine in metastatic breast cancer patients in the Unicancer ESME database [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-15-12.